A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Conditions: Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation Interventions: Drug: NST-628 Sponsors: Nested Therapeutics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Conditions: Breast Cancer; Lung Cancer; Melanoma; Head and Neck Cancer; Urothelial Carcinoma; Colorectal Cancer; Liver Metastases; Lung Metastases Interventions: Genetic: Cohort A: primarily operable disease, candidate to adjuvant; Genetic: Cohort B: locally advanced disease; Genetic: Cohort C: metastatic disease; Genetic: Cohort D: Progressive disease; Genetic: Cohort E: Hematological neoplasms; Genetic: Cohort F: Toxicity Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
Conditions: Skin Melanoma Interventions: Drug: RPH-075; Drug: Keytruda ® Sponsors: R-Pharm; Data Management 365; Exacte Labs LLC; Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Conditions: Cutaneous Melanoma; Melanoma Stage IV; Mucosal Melanoma Interventions: Drug: Opdualag; Drug: Nivolumab Sponsors: University Health Network, Toronto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda ® in Patients With Malignant Neoplasms
Conditions: Skin Melanoma; Squamous Non-small-cell Lung Cancer; Head and Neck Squamous Cell Carcinoma Interventions: Drug: RPH-075; Drug: Keytruda ® Sponsors: R-Pharm; Data Management 365; Exacte Labs LLC; Federal State Budgetary Institution " NMIC of Hematology " of the Ministry of Health of the Russian Federation; Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Conditions: Melanoma; Head and Neck Squamous Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Solid Tumor Interventions: Drug: IPN01194; Drug: IPN01194 Sponsors: Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]
Conditions: Melanoma, Skin; Melanoma Stage Iii Interventions: Diagnostic Test: Gut microbiota analysis Sponsors: Russian Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Exercise and Diet Interventions During Immunotherapy in Melanoma Patients
Conditions: Melanoma (Skin); Skin Cancer; Advanced Melanoma Interventions: Behavioral: Exercise Program; Behavioral: Diet Program Sponsors: Dana-Farber Cancer Institute; World Cancer Research Fund International Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma Interventions: Biological: NM32-2668 Sponsors: Numab Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
New clinical study published demonstrates superiority of AI-algorithm guided melanoma diagnosis
STOCKHOLM, March 6, 2024. Results from a prospective, multicentre, clinical trial published today in the peer-reviewed British Journal of Dermatology showed that AI helps significantly improve melanoma detection rates.
The trial, conducted in 37... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Conditions: Melanoma Stage III; Melanoma Stage IV; Advanced Melanoma; Melanoma Interventions: Drug: Nivolumab; Drug: Nivolumab + Relatlimab; Drug: Ipilimumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy
Conditions: Malignant Melanoma Sponsors: Odense University Hospital; University of Copenhagen; Aarhus University Hospital; Aalborg University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus
Conditions: Primary Malignant Melanoma of the Esophagus Sponsors: Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Conditions: Advanced Solid Tumor; RAF Mutation; RAS Mutation; NF1 Mutation; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Melanoma; BRAF Gene Mutation; CRAF Gene Mutation Interventions: Drug: DCC-3084 Sponsors: Deciphera Pharmaceuticals LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Conditions: Cutaneous Squamous Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
